



(12) Translation of
European patent specification

(11) NO/EP 4028001 B1

NORWAY

(19) NO

(51) Int Cl.

A61K 31/546 (2006.01)

A61K 9/00 (2006.01)

A61K 31/438 (2006.01)

A61K 38/12 (2006.01)

A61P 31/04 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2024.07.29
(80)	Date of The European Patent Office Publication of the Granted Patent	2024.04.10
(86)	European Application Nr.	20768692.4
(86)	European Filing Date	2020.08.03
(87)	The European Application's Publication Date	2022.07.20
(30)	Priority	2019.09.12, US, 201962899257 P 2019.09.18, US, 201962902019 P 2019.11.27, US, 201962941160 P 2020.02.17, US, 202062977659 P
(84)	Designated Contracting States:	AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR
(73)	Proprietor	Bioversys AG, Technologiepark Basel Hochbergerstrasse 60c, 4057 Basel, Sveits
(72)	Inventor	DALE, Glenn, E., C.F. Meyer-Strasse 10, 4059 Basel, Sveits LOCIURO, Sergio, Fasanenstrasse 121, 4058 Basel, Sveits KEMMER, Christian, Störklingasse 40, 4125 Riehen, Sveits TREBOSC, Vincent, 12D Rue des Sangliers, 68170 Rixheim, Frankrike GITZINGER, Marc, Hochbergerstrasse 60c c/o Technologiepark, 4057 Basel, Sveits
(74)	Agent or Attorney	Novagraaf Brevets, Bâtiment O2, 2 rue Sarah Bernhardt CS90017, 92665 ASNIÈRES-SUR-SEINE CEDEX, Frankrike

(54)	Title	RIFABUTIN TREATMENT METHODS, USES, AND COMPOSITIONS
(56)	References Cited:	US-A1- 2019 269 806 US-A1- 2020 222 373 WO-A1-2012/106364 RAJAMANI SATHISH ET AL: "Robust biofilm assay for quantification and high throughput screening applications", JOURNAL OF MICROBIOLOGICAL METHODS, vol. 159, 28 February 2019 (2019-02-28), pages 179-185, XP085650229, ISSN: 0167-7012, DOI: 10.1016/J.MIMET.2019.02.018 DARREN WONG ET AL: "SUMMARY", CLINICAL MICROBIOLOGY REVIEW, vol. 30, no. 1, 14 December 2016 (2016-12-14), pages 409-447, XP055741808, US ISSN: 0893-8512, DOI: 10.1128/CMR.00058-16 NWUGO C C ET AL: "Deciphering the iron response in Acinetobacter baumannii: A proteomics approach", JOURNAL OF PROTEOMICS, ELSEVIER, AMSTERDAM, NL, vol. 74, no. 1, 1 January 2011 (2011-01-01), pages 44-58, XP027544315, ISSN: 1874-3919 [retrieved on 2010-08-06]

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

PATENTKRAV

1. Sammensetning for anvendelse ved behandling av *A. baumannii*-infeksjon, sammensetningen omfattende vann, et løsningsmiddel, en syre og rifabutin for intravenøs levering i en dose som er minst ca. 2 mg/kg per døgn,
5 1 mg/kg hver 12. time eller 0,5 mg/kg hver 6. time.
 2. Sammensetningen for anvendelse ifølge krav 1, hvori løsningsmidlet velges fra gruppen som består av polyoksyetylensorbitanmonooleat (Tween 80), sorbitanmonooleatpolyoksyetylensorbitanmonolaurat (Tween 20), polyetylglykol (PEG), propylenglykol, N-metyl-2-pyrrolidon (NMP), glyserin, etanol,
10 dimetylacetamid (DMA), dietylglykolmonoetyler (transkutol HP) og dimetylisosorbid (DMI).
 3. Sammensetningen for anvendelse ifølge krav 1, hvori sammensetningen omfatter ca. 2:1 løsningsmiddel:rifabutin.
 4. Sammensetningen for anvendelse ifølge krav 1, hvori sammensetningen
15 er tilveiebrakt som en vandig løsning for intravenøs levering.
 5. Intravenøs pose omfattende sammensetningen for anvendelse ifølge et hvilket som helst av kravene 1 til 4.
-